The revolutionary improvement in clinical outcomes conferred by CDK4/6 inhibitors in HR+/HER2- BC has fueled the design of preclinical [12,13] and early-phase clinical [14] studies investigating their activity in the triple-negative BC (TNBC) subtype, with early results suggesting their potential use in some patient subgroups. This evidence concerns the gene CDK4 and breast cancer.